Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS.
Journal: Future oncology (London, England)
Published: October 27, 2025
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.
Journal: JCO precision oncology
Published: August 18, 2025
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
Journal: Nature communications
Published: July 25, 2025
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.
Journal: The oncologist
Published: May 13, 2024
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Journal: Journal for immunotherapy of cancer
Published: September 07, 2023
Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Journal: Journal of geriatric oncology
Published: March 23, 2023
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Journal: Journal for immunotherapy of cancer
Published: June 15, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 11, 2022
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 04, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 02, 2021
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: October 25, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026